Key Highlights

  • SCWorx (NASDAQ:WORX) rose 6.34% to USD 2.18 in a pre-market snapshot on Tuesday, October 27, 2026, after the Nasdaq Hearings Panel approved continued listing on Friday, October 2, 2026 and trading resumed on Wednesday, October 7, 2026.
  • Davion Healthcare (NASDAQ:DAVI) fell 8.85% to USD 3.71 after the company's release of Monday, October 26, 2026 on the completed purchase of intellectual property from Humaskan, priced at about USD 25 million and paid mostly in shares.
  • INVO Fertility (NASDAQ:IVF) fell 5.98% to USD 0.5359 with no dated announcement, while second quarter 2026 net income of USD 888,740 included a non-cash remeasurement gain of USD 2,452,032.
  • XWELL (NASDAQ:XWEL) fell 5.70% to USD 0.711 with no dated announcement, while its agreed USD 13 million sale of the airport spa and testing businesses awaits closing.

SCWorx (NASDAQ:WORX): a restored listing on a thin float

SCWorx (NASDAQ:WORX), a provider of data management and normalisation services for healthcare supply chains, moved without a company-specific announcement dated on or just before Tuesday, October 27, 2026. The most recent release, of Monday, October 19, 2026, announced an agreement with an independent, community-owned health system with financial terms not disclosed. The move appears consistent with continued interest after the return to trading and with thin liquidity, and both readings are inferences. The company is subject to a Panel Monitor, a one-year compliance watch, through Saturday, October 2, 2027, after a suspension of trading on Tuesday, April 14, 2026 for failing the USD 1.00 minimum bid price rule.

The company's release of Wednesday, October 7, 2026 gave unaudited first half 2026 figures. Revenue was about USD 1.45 million, against about USD 1.40 million, gross profit rose about 122% to USD 705,000 and the net loss narrowed to about USD 295,000 from USD 2.4 million. Cash was about USD 1.3 million at Tuesday, June 30, 2026. The company sold 350,000 units at USD 2.68 each on Thursday, September 17, 2026, with five-year warrants exercisable at USD 2.56, and publicly held shares were only 549,092, close to the 500,000 minimum. The bear reading rests on nearly flat revenue, dilution from the warrants and dependence on a small number of healthcare customers.

Davion Healthcare (NASDAQ:DAVI): a share-funded acquisition before revenue

Davion Healthcare Plc (NASDAQ:DAVI), an Irish company that develops non-invasive home screening tests, implies a prior close near USD 4.07, by simple arithmetic on the snapshot. The assets acquired from the four shareholders of Humaskan are WoundSkan, a wound-monitoring dressing, and Spektra, a multi-marker screening platform that the release states is not a diagnostic test. Consideration comprises USD 2.5 million in cash, payable by Friday, February 19, 2027, and 1,730,770 new ordinary shares due for issue on Wednesday, January 20, 2027 at a fixed value of USD 13.00 each. The release also referred to a GBP 30 million five-year senior secured bond launched to fund an acquisition programme.

The share count is fixed, so the value delivered to sellers varies with the market price. The registration statement of Friday, December 5, 2025 reported no revenue, with operating losses of EUR 0.3 million for the six months to June 30, 2025. Trading on the Nasdaq Global Market was expected to begin on Thursday, October 22, 2026, so the price history is short. The bull reading is that the acquisition broadens a pipeline beyond BreastCheck. The bear reading is that the shares trade well below the fixed deal value, that the bond adds fixed obligations and that the tests are described as non-diagnostic devices registered under self-declaration.

INVO Fertility (NASDAQ:IVF): clinic growth and a non-cash gain

INVO Fertility (NASDAQ:IVF), an operator of fertility clinics and a provider of an intravaginal culture device for in vitro fertilisation, fell without a company-specific announcement. The decline therefore appears consistent with the thin liquidity of pre-market sessions and with the volatility of a micro-cap stock priced below USD 1.00. The most recent formal disclosure was the release of Monday, August 17, 2026, which reported revenue of USD 2,175,485 for the quarter ended June 30, 2026, up 17% from USD 1,863,654. Net income compared with a net loss of USD 3,618,969 a year earlier, but the non-cash gain on remeasurement tied to the Birmingham, Alabama clinic explains the swing.

Adjusted EBITDA, a non-GAAP measure of operating earnings, was a loss of USD 1,032,660 against a loss of USD 587,229. Cash was USD 3.7 million, and the company gave no quantitative guidance. The bull reading rests on the full-quarter contribution of Family Beginnings in Indiana, acquired in February 2026, and full ownership of the Birmingham clinic from June 2026. The bear reading rests on the wider loss and on listing compliance, given Nasdaq late-filing notices for the Form 10-K and a Form 10-Q and a 1-for-5 reverse split effective Friday, March 27, 2026.

XWELL (NASDAQ:XWEL): a divestiture that removes the revenue base

XWELL (NASDAQ:XWEL), a wellness and biosecurity company that is selling its airport spa and testing businesses, fell without a company-specific announcement dated on or just before the session. The most recent corporate item was the divestiture agreement of Tuesday, July 7, 2026, under which XpresSpa Holdings and XpresTest go to Express Wellness Group, subject to adjustments, with closing expected later in 2026. The decline appears consistent with thin pre-market liquidity and the pressure on low-priced shares, which is an inference.

The earnings summary for the six months ended June 30, 2026 reported revenue of about USD 13.8 million, down 6%, a net loss of about USD 12.9 million, operating cash burn of about USD 9.1 million and cash of about USD 12.3 million. A private placement announced on Tuesday, February 24, 2026 was expected to raise about USD 31.3 million gross, so the cash balance reflects that financing rather than operating inflow. The bull reading is that the sale proceeds fund a pivot towards biosecurity. The bear reading is that revenue falls sharply once the airport businesses leave and that a quote below USD 1.00 sits under the Nasdaq minimum bid price level.

Where Things Stand

The answer is that the four names differ in what a small balance sheet must absorb. SCWorx (NASDAQ:WORX) must hold a restored listing under a compliance watch. Davion Healthcare (NASDAQ:DAVI) must carry a share-funded acquisition before it reports revenue. INVO Fertility (NASDAQ:IVF) must turn clinic growth into operating earnings rather than non-cash gains. XWELL (NASDAQ:XWEL) must replace the airport revenue it has agreed to sell.

The next catalysts are the Federal Reserve decision of Wednesday, October 28, 2026, which follows the rate rise from 3.75% to 4.00% on Wednesday, September 16, 2026, the release of the segregated SCWorx proceeds on Monday, November 30, 2026, the Davion Healthcare share issue on Wednesday, January 20, 2027 and the closing of the XWELL divestiture later in 2026. INVO Fertility has its third-quarter 2026 results ahead. Pre-market prices are snapshots and can change before the open at 9:30 a.m. ET, and this is not investment advice.